WO2000009525A3 - Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments - Google Patents

Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments Download PDF

Info

Publication number
WO2000009525A3
WO2000009525A3 PCT/US1999/017712 US9917712W WO0009525A3 WO 2000009525 A3 WO2000009525 A3 WO 2000009525A3 US 9917712 W US9917712 W US 9917712W WO 0009525 A3 WO0009525 A3 WO 0009525A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
cancer
lung
mrna
treatments
Prior art date
Application number
PCT/US1999/017712
Other languages
French (fr)
Other versions
WO2000009525A2 (en
Inventor
Jonathan W Nyce
Original Assignee
Univ East Carolina
Jonathan W Nyce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ East Carolina, Jonathan W Nyce filed Critical Univ East Carolina
Priority to AU53374/99A priority Critical patent/AU5337499A/en
Priority to EP99939006A priority patent/EP1102786A4/en
Priority to CA002333901A priority patent/CA2333901A1/en
Publication of WO2000009525A2 publication Critical patent/WO2000009525A2/en
Publication of WO2000009525A3 publication Critical patent/WO2000009525A3/en
Priority to HK02102614.0A priority patent/HK1042706A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C

Abstract

A composition comprises a nucleic acid comprising an oligo anti-sense to a target such as polypeptide(s) associated with an ailment afflicting lung airways, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixtures. Various formulations contain a requisite carrier, and optionally other additives and biologically active agents. The agent of the invention may be prepared by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) associated with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the mRNA segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepared by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the anti-sense oligonucleotides with a AUniversal base@. The agent, composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, allergy(ies) and/or inflammation, such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, pulmonary hypertension and bronchoconstriction, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), ischemic conditions including ischemia itself, and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastasis, etc., as well as all types of cancers with may metastasize or have metastasized to the lung(s), including breast and prostate cancer. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. The present agent is effectively administered preventatively, prophylactically or therapeutically by itself for conditions without known therapies, or as a substitute for, or in conjunction with, other therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject, so that the agent has direct access to the airways and the lungs.
PCT/US1999/017712 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments WO2000009525A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU53374/99A AU5337499A (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
EP99939006A EP1102786A4 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
CA002333901A CA2333901A1 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
HK02102614.0A HK1042706A1 (en) 1998-08-03 2002-04-08 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9521298P 1998-08-03 1998-08-03
US60/095,212 1998-08-03

Publications (2)

Publication Number Publication Date
WO2000009525A2 WO2000009525A2 (en) 2000-02-24
WO2000009525A3 true WO2000009525A3 (en) 2000-05-18

Family

ID=22250687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017712 WO2000009525A2 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Country Status (6)

Country Link
EP (1) EP1102786A4 (en)
CN (1) CN1317009A (en)
AU (1) AU5337499A (en)
CA (1) CA2333901A1 (en)
HK (1) HK1042706A1 (en)
WO (1) WO2000009525A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
WO2000058468A2 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 47 human secreted proteins
AU3766800A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 48 human secreted proteins
AU4031700A (en) * 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
US6489151B1 (en) * 2000-03-27 2002-12-03 The Research Foundation Of State University Of New York Biologically active alternative form of the IKKα IκB kinase
DE10019252A1 (en) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydeoxyribonucleotides to inhibit ICAM-1 gene expression
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
MXPA04000162A (en) * 2001-07-06 2006-05-22 Topigen Pharma Inc Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals.
US20060088835A1 (en) * 2002-04-05 2006-04-27 Pickard Benjamin S Schizophrenia associated genes
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
CN1322899C (en) * 2004-02-11 2007-06-27 中国科学院上海生命科学研究院 Anti cancer gene medicinal composition, micromolecule interfere RNA and its screening method
BRPI0517387A8 (en) 2004-10-29 2017-07-11 Topigen Pharmaceuticals Inc ANTI-SENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF ALLERGY AND NEOPLASTIC CELL PROLIFERATION
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
RU2584573C2 (en) * 2011-06-15 2016-05-20 Грайфолз Терепьютикс Инк. Methods, compositions and kits for detection of human immunodeficiency virus (hiv)
CN102866153B (en) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 Prostatitis joint-detection kit
EP2970978A4 (en) * 2013-03-11 2016-11-02 Univ North Carolina Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
WO2022094320A2 (en) * 2020-10-29 2022-05-05 Garcia Blanco Mariano A Soluble interleukin-7 receptor (sil7r) modulating therapy to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3739785B2 (en) * 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド Enhanced triple and double helix shaping using oligomers containing modified pyrimidines
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP2002515513A (en) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for pulmonary delivery of nucleic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NYCE ET AL.: "DNA antisense therapy for asthma in an animal model", NATURE,, vol. 385, 20 February 1997 (1997-02-20), pages 721 - 725, XP002923989 *
See also references of EP1102786A4 *

Also Published As

Publication number Publication date
AU5337499A (en) 2000-03-06
WO2000009525A2 (en) 2000-02-24
CN1317009A (en) 2001-10-10
EP1102786A4 (en) 2002-03-06
HK1042706A1 (en) 2002-08-23
EP1102786A2 (en) 2001-05-30
CA2333901A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
WO2000009525A3 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
US10369232B2 (en) Allele selective gene editing and uses thereof
US9101646B2 (en) Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
DE69434960D1 (en) Gene therapy for solid tumors, papillomas and warts
EP2386312A3 (en) Intrathecal and intratumoral superantigens to treat malignant disease
AU2003237616A1 (en) Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
JP2007505954A5 (en)
BR0006019A (en) Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion
US9334496B2 (en) Antisense EGFRAS guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
Miyake et al. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic
JP2017510583A (en) Transthyretin allele-selective UNA oligomers for gene silencing
Koutsilieris et al. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone‐refractory prostate cancer: Case report
US20130237584A1 (en) CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
MXPA01008870A (en) Method for validating/invalidating target(s) and pathways.
AU2001290920B2 (en) Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
ES2201611T3 (en) USE OF MAGNESIUM (MG2 +) TO INCREASE THE INTRODUCTION OF GENES IN GENE THERAPY.
US20240067684A1 (en) Constitutively active payloads
JP2004510761A5 (en)
Baba et al. Ha‐ras mutations in N‐nitrosomorpholine‐induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver
Lokich Metastatic adamantinoma of bone to lung: a case report of the natural history and the use of chemotherapy and radiation therapy
JP2021505200A5 (en)
WO2001057069A3 (en) Targeting peptides
ES2919898B2 (en) New treatment for colorectal cancer
TW202408541A (en) Formulations for modulating myc expression
JP2003503308A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809303.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN MX RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN MX RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 53374/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2333901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000971

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999939006

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939006

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999939006

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)